Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite
New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression
GAITHERSBURG, Md., Jun 9, 2002 - Gene Logic Inc., a leading provider of integrated genomics information and bioinformatics products and services, announced today the latest GeneExpress(R) product introduction, the GeneExpress Women's Health DataSuite(TM). The formal launch occurred during the biotechnology Industry Organization (BIO) Annual Conference, in Toronto, Canada.
The Women's Health DataSuite is designed for use by pharmaceutical and biotechnology companies interested in developing products specific for women and based on differences between women and men. Targets identified through gene expression can be used for drug development and to optimize preclinical and clinical development. The Women's Health DataSuite will consist of gene expression information gathered from female human tissues representing key conditions, disorders and disease states, including menopause, fertility, osteoporosis, osteoarthritis, cancer, autoimmune diseases, heart disease and reproductive disorders. These gene expression data are combined with extensive patient and clinical descriptions, including pathological and clinical descriptions, full medical history, medication history, obstetric/gynecologic findings, histopathology images and applicable specimen collection conditions (anesthetic drug, time from surgery to freezing, post-mortem intervals).
The Women's Health DataSuite enables researchers to conduct in silico analyses across a broad spectrum of normal and diseased female human tissues to achieve rapid, accurate and detailed comparisons of gene expression profiles, and could provide a basis to develop individualized therapies, more predictive biomarkers, and improved diagnostics.
The Women's Health DataSuite is currently available for subscription; fees will be comparable to fees for other Gene Logic DataSuite products.
Dr. Marietta Anthony, Scientific Director, Women's Health Program at Gene Logic commented, "Our strategy in creating tools based on gene expression to assess women's health issues is twofold: (i) for conditions/diseases unique to women, and (ii) for conditions/diseases that may affect women differently from men. We know that there are important biological sex differences between women and men in both the healthy and diseased state. Using gene expression to explore these differences on a molecular level can help to identify new drug targets and develop therapeutics and diagnostics specific for women."
David S. Murray, Senior Vice President for Marketing and Sales at Gene Logic stated, "The Women's Health DataSuite represents a powerful evolution of our information-centric business model, in that we have captured specific data from GeneExpress to create a novel information product that addresses the research needs of an important scientific and market opportunity. This product adds a new genomic dimension to an important area of interest for our pharmaceutical and biotechnology customers."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
